Search results for "antihypertensive agents"

showing 10 items of 184 documents

MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled tr…

2018

Introduction Masked uncontrolled hypertension (MUCH) carries an increased risk of cardiovascular (CV) complications and can be identified through combined use of office (O) and ambulatory (A) blood pressure (BP) monitoring (M) in treated patients. However, it is still debated whether the information carried by ABPM should be considered for MUCH management. Aim of the MASked-unconTrolled hypERtension management based on OBP or on ambulatory blood pressure measurement (MASTER) Study is to assess the impact on outcome of MUCH management based on OBPM or ABPM. Methods and analysis MASTER is a 4-year prospective, randomised, open-label, blinded-endpoint investigation. A total of 1240 treated hyp…

HYPERTENSION MANAGEMENTHipertensión.1302masked uncontrolled hypertensionEnfermedades cardiovasculares - Pacientes - Factores de riesgo.office blood pressureMASKED UNCONTROLLED HYPERTENSIONMedicina ClínicaCardiovascular Medicine030204 cardiovascular system & hematologyAMBULATORY BLOOD PRESSURE MONITORINGlaw.invention0302 clinical medicineClinical trialsRandomized controlled triallawBlood Pressure MonitoringMasked Hypertension//purl.org/becyt/ford/3.2 [https]ProtocolMulticenter Studies as Topic1506030212 general & internal medicineCardiovascular system - Diseases - Patients - Risk factors.Blood pressure.OFFICE BLOOD PRESSURERandomized Controlled Trials as TopicSistemas Cardíaco y CardiovascularGeneral MedicineBlood Pressure Monitoring Ambulatory3. Good healthCor MalaltiesEchocardiographyAmbulatoryHypertensionBlood pressure//purl.org/becyt/ford/3 [https]Hipertensióambulatory blood pressure monitoring; hypertension; hypertension management; masked uncontrolled hypertension; office blood pressure; treated hypertensive patientsTREATED HYPERTENSIVE PATIENTS1683medicine.medical_specialtyAmbulatory blood pressureCIENCIAS MÉDICAS Y DE LA SALUDhypertensionHeart Ventriclestreated hypertensive patientPressió sanguínia03 medical and health sciencesAmbulatoryHypertension.medicineAlbuminuriaHumansAntihypertensive AgentsProtocol (science)business.industryConsolidated Standards of Reporting Trialsambulatory blood pressure monitoring; hypertension; hypertension management; masked uncontrolled hypertension; office blood pressure; treated hypertensive patients; Albuminuria; Antihypertensive Agents; Echocardiography; Heart Ventricles; Humans; Masked Hypertension; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Blood Pressure Monitoring Ambulatorytreated hypertensive patientsambulatory blood pressure monitoringBlood pressurePresión sanguínea.Good clinical practiceEmergency medicinebusinessDeclaration of Helsinkihypertension managementAssaigs clínicsBMJ Open
researchProduct

The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications.

2002

Adjunctive therapy for the management of glaucoma is commonly used. Unfixed combinations of the prostaglandin analog latanoprost and other glaucoma medications have been demonstrated to effectively lower intraocular pressure (IOP). The range of reported additional reductions in IOP compared to a monotherapy baseline are as follows: latanoprost-timolol (13-37%), latanoprost-pilocarpine 2% (7-14%), latanoprost and carbonic anhydrase inhibitors (15-24.1%), and latanoprost and dipivefrin (15-28%). There is a fixed combination of latanoprost (0.005%) and timolol (0.5%) that has been investigated in Phase III trials in Europe and the United States. In these trials, it was noted that the efficacy …

Intraocular pressureMydriaticsgenetic structuresCombination therapymedicine.medical_treatmentAdrenergic beta-AntagonistsTimololGlaucomachemistry.chemical_compoundMedicineHumansLatanoprostCarbonic Anhydrase InhibitorsAntihypertensive AgentsIntraocular PressureChemotherapyDipivefrinbusiness.industryGlaucomamedicine.diseaseeye diseasesOphthalmologyProstaglandin analogchemistryAnesthesiaProstaglandins F SyntheticLatanoprostDrug Therapy CombinationOcular Hypertensionsense organsOphthalmic SolutionsSafetybusinessmedicine.drugSurvey of ophthalmology
researchProduct

Update on topical carbonic anhydrase inhibitors

2001

Topical carbonic anhydrase inhibitors are a novel addition to the armamentarium of medical glaucoma treatment; dorzolamide has been available since 1995 and brinzolamide since 1998. They lower intraocular pressure by inhibiting carbonic anhydrase, a key enzyme for aqueous humor formation. Intraocular pressure-lowering activity of the substances appears to be the same and is similar to that of most other agents, but it does not reach the activity of the unselective beta-blocker timolol or the prostaglandin latanoprost. On concomitant treatment, additivity is reached with all other topical agents. A possible improvement of blood flow may offer an additional benefit, but its significance for t…

Intraocular pressuregenetic structuresBrinzolamideThiazinesGlaucomaTimololThiophenesPharmacologyEyeAqueous Humorchemistry.chemical_compoundDorzolamideCarbonic anhydrasemedicineHumansLatanoprostCarbonic Anhydrase InhibitorsAntihypertensive AgentsIntraocular PressureCarbonic Anhydraseschemistry.chemical_classificationSulfonamidesDose-Response Relationship Drugbiologybusiness.industryGlaucomaGeneral Medicinemedicine.diseaseeye diseasesOphthalmologyEnzymechemistryProstaglandins F Syntheticbiology.proteinLatanoprostsense organsOphthalmic SolutionsbusinessBlood Flow Velocitymedicine.drugCurrent Opinion in Ophthalmology
researchProduct

Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma.

2014

Lowering intraocular pressure (IOP) is at present the only therapeutic approach to the treatment of glaucoma proven to be successful. The choice of therapy must take into account efficacy, tolerability, safety, quality of life, adherence and cost. Monotherapy fails to achieve a satisfactory IOP reduction in 40 - 75% of glaucoma patients after2 years of therapy. So far, three prostaglandin/timolol maleate 0.5% fixed combinations (FCs) are available.This review provides a background on the tafluprost-timolol FC (TTFC, Santen Oy) and its individual compounds. It summarizes the data on efficacy and safety, including comparative data with prostaglandin/timolol FCs already available.Tafluprost is…

Intraocular pressuregenetic structuresOpen angle glaucomaDrug-Related Side Effects and Adverse ReactionsOcular hypertensionTimololGlaucomamedicineHumansPharmacology (medical)Antihypertensive AgentsPharmacologybusiness.industryProstaglandins FTafluprostGlaucomaGeneral Medicinemedicine.diseaseeye diseasesDrug CombinationsProstaglandin analogTolerabilityAnesthesiaTimololDrug Evaluationlipids (amino acids peptides and proteins)Ocular Hypertensionsense organsbusinessGlaucoma Open-Anglemedicine.drugExpert opinion on pharmacotherapy
researchProduct

Intercurrent factors associated with the development of open-angle glaucoma in The European Glaucoma Prevention Study

2007

Purpose: To evaluate the intercurrent factors for the development of open-angle glaucoma (OAG) in ocular hypertensive patients who were enrolled in the European Glaucoma Prevention Study (EGPS). Design: Randomized, double masked, controlled clinical trial. Methods: setting: Multicenter. study population: A total of 1,077 patients fulfilled a series of inclusion criteria, including intraocular pressure (IOP) 22 to 29 mm Hg, normal and reliable visual fields (VFs) and normal optic disks. intervention: Treatment with dorzolamide or placebo. main outcome measures: Glaucoma-related VF or optic disk changes. Clinical data were collected every six months during a five-year follow-up. Proportional …

Intraocular pressuremedicine.medical_specialtyTime Factorsgenetic structuresOpen angle glaucomaSettore MED/06 - Oncologia MedicaOptic DiskOptic diskOcular hypertensionGlaucomaThiopheneslaw.inventionCorneaDouble-Blind MethodDorzolamideRandomized controlled trialRisk FactorslawOphthalmologyConfidence IntervalsPrevalencemedicineHumansDiureticsglaucoma ocular hypertension intercurrent risk factorsAntihypertensive AgentsIntraocular PressureProportional Hazards ModelsRetrospective StudiesSulfonamidesbusiness.industryHazard ratioRetinal Hemorrhagemedicine.diseaseeye diseasesEuropeOphthalmologyTreatment OutcomeCardiovascular Diseasessense organsbusinessGlaucoma Open-AngleFollow-Up Studiesmedicine.drug
researchProduct

Vasoactive properties of antihypertensive lactoferrin-derived peptides in resistance vessels: Effects in small mesenteric arteries from SHR rats

2017

Aims: Bovine lactoferrin (LF) hydrolysates and peptides identified thereof have shown antihypertensive effects in rat models, mainly but not exclusively by angiotensin-converting enzyme inhibition. In this study we aimed to assess the vasoactive effects and mechanisms of an ultrafiltered (< 3 kDa) pepsin LF hydrolysate (LFH) and a heptapeptide identified in a LF hydrolysate produced by yeast proteolysis (DPYKLRP) in peripheral resistance arteries from spontaneously hypertensive rats (SHRs). Main methods: We used a myograph system for isometric tension recording in isolated small mesenteric arteries from SHRs. Direct vasoactive effects of LFH (30–100 μg/mL) and DPYKLRP (30–100 μM) were asses…

Male0301 basic medicinemedicine.medical_specialtyProtein HydrolysatesAntihypertensive effectsBlood PressureLactoferrin-derived peptidesIn Vitro TechniquesGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesSpontaneously hypertensive ratIn vivoRats Inbred SHRInternal medicinemedicineAnimalsGeneral Pharmacology Toxicology and PharmaceuticsPhenylephrineMesenteric arteriesAntihypertensive AgentsSpontaneously hypertensive rat030109 nutrition & dieteticsDose-Response Relationship Drugbiologybusiness.industryMesenteric arteryVasorelaxationGeneral MedicineAction mechanismMesenteric ArteriesVasodilationLactoferrinEndocrinologymedicine.anatomical_structureHypertensionbiology.proteinVascular ResistanceCyclooxygenaseSodium nitroprussidebusinessOligopeptidesAcetylcholinemedicine.drugMyograph
researchProduct

The prescription of direct oral anticoagulants in the elderly: An observational study of 19 798 Ambulatory subjects.

2020

International audience; Objective Direct oral anticoagulants (DOACs) are increasingly prescribed to elderly people, but the epidemiologic data for this population remains scarce. We compared the elderly population taking DOACs and those not taking DOACs (noDOAC). Method We included individuals over 75 years old, affiliated to Mutualite Sociale Agricole of Burgundy (a French regional health insurance agency), who had been refunded for a prescribed DOAC between 1st and 30th September 2017. The DAOC group (DAOCG) and noDOAC group (noDOACG) were compared in terms of demographic conditions, registered chronic diseases (RCD), and number and types of prescribed drugs. In the DOACG, we compared the…

MaleAdministration Oral030204 cardiovascular system & hematologyKidney Function Tests0302 clinical medicineRivaroxabanMedicineDisease030212 general & internal medicineProspective StudiesPractice Patterns Physicians'Aged 80 and overeducation.field_of_studyFrailtyVenous ThromboembolismGeneral MedicineMetaanalysisManagement3. Good healthDabigatranHealthCreatinineAmbulatoryPlatelet aggregation inhibitorApixabanFemaleBlood Coagulation TestsFranceSafetymedicine.drugmedicine.medical_specialtyPyridonesPopulationDrug PrescriptionsDabigatran03 medical and health sciencesInternal medicineHumansMedical prescriptioneducationAntihypertensive AgentsAgedRivaroxabanbusiness.industryWarfarinAnticoagulantsBlood Cell CountAtrial-FibrillationChronic DiseasePyrazolesWarfarinbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyPlatelet Aggregation InhibitorsInternational journal of clinical practiceREFERENCES
researchProduct

Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension:A Double-Blind Placebo-controlled Clinical Trial

2020

Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hypertension (PAH), but the effect on clinical outcomes was unknown.\ud \ud Objectives: To evaluate the effect of oral treprostinil compared with placebo on time to first adjudicated clinical worsening event in participants with PAH who recently began approved oral monotherapy.\ud \ud Methods: In this event-driven, double-blind study, we randomly allocated 690 participants (1:1 ratio) with PAH to receive placebo or oral treprostinil extended-release tablets three times daily. Eligible participants were using approved oral monotherapy for over 30 days before randomization and had a 6-minute-walk dista…

MaleAdministration OralOral treprostinilCritical Care and Intensive Care MedicinePulmonary arterial hypertension[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractcombination therapyoralepoprostenol0302 clinical medicinepulmonary arterial hypertensionmiddle agedClinical endpointdouble-blind methodMESH: Double-Blind MethodFamilial Primary Pulmonary Hypertension030212 general & internal medicinehumansMESH: AgedMESH: Middle AgedEpoprostenol/analogs & derivativesadultHazard ratioMiddle Aged[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciencesantihypertensive agents3. Good healthagedfemaleMESH: Young Adultoral treprostinilMESH: Administration Oralyoung adultFemalePulmonary Arterial Hypertension/drug therapymedicine.drugAdultPulmonary and Respiratory MedicineMESH: Pulmonary Arterial Hypertensionmedicine.medical_specialtyRandomizationAdolescentclinical study; combination therapy; oral treprostinil; pulmonary arterial hypertension; sequential therapy; administration oral; adolescent; adult; aged; antihypertensive agents; double-blind method; epoprostenol; female; humans; male; middle aged; placebos; pulmonary arterial hypertension; young adultSequential therapyMESH: PlacebosMESH: EpoprostenolLower riskPlaceboadministrationClinical studyYoung Adult03 medical and health sciencesDouble-Blind Method[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmaleInternal medicineplacebosmedicineHumansCombination therapyAdverse effectPlacebos/therapeutic useAgedMESH: AdolescentPulmonary Vascular DiseaseMESH: Antihypertensive AgentsMESH: Humanssequential therapybusiness.industryMESH: AdultOriginal Articlesclinical studyMESH: MaleClinical trial030228 respiratory systemadolescentAntihypertensive Agents/administration & dosagebusinessMESH: FemaleTreprostinil
researchProduct

Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension

2000

To investigate the efficacy and tolerability of lercanidipine, used as monotherapy once a day, in elderly patients with isolated systolic hypertension (ISH), 83 patients were enrolled in this multicenter, double-blind, randomized, placebo-controlled study. All patients were older than 60 years, and their mean age was 66.7 +/- 5.4 years. ISH was defined as SBPor = 160 mmHg, and DBP95 mmHg. After wash-out and placebo run-in periods, patients were randomly assigned to placebo or lercanidipine (10 mg once a day) treatment for 4 weeks. Non-responding patients of the lercanidipine-treated group were later treated with 20 mg of lercanidipine once a day for 4 additional weeks. At the end of the stu…

MaleAgingDihydropyridinesSystoleBlood PressurePlaceboPlacebo groupOrthostatic vital signsDouble-Blind MethodDiastoleHeart ratemedicineHumansAntihypertensive AgentsAgedbusiness.industryLercanidipineMiddle AgedBlood pressureTreatment OutcomeTolerabilityAnesthesiaIsolated systolic hypertensionHypertensionFemaleGeriatrics and Gerontologybusinessmedicine.drug
researchProduct

Changes in blood pressure in a large cohort of elderly individuals: Study 3C

2009

Summary Objective Analysis of changes in blood pressure with a two-year interval, and of factors associated with this change, in a large cohort of elderly individuals. Methods Follow-up of a cohort of 9294 individuals aged 65 years and over recruited from the general population for Study 3C. Changes in blood pressure are defined as the difference in its averages between the inclusion visit and the follow-up visit at 2 years. The factors associated with changes in systolic blood pressure were identified by univariate and multivariate analyses. Results Systolic and diastolic blood pressure decreased on average by 7.60 mmHg and 4.45 mmHg respectively in 7659 individuals included in the study b…

MaleAgingmedicine.medical_specialtyTime FactorsMultivariate analysisRégression vers la moyennePopulationPression artérielleHypertension artériellePredictive Value of TestsAntihypertensive treatmentRegression toward the meanInternal medicineEpidemiologymedicineHumanseducationRegression towards the meanTraitement antihypertenseurAntihypertensive AgentsAgedAged 80 and overeducation.field_of_studybusiness.industryAge FactorsCohortUnivariateReproducibility of ResultsBlood Pressure DeterminationGeneral MedicineCohorteBlood pressureMultivariate AnalysisHypertensionCohortBlood pressureCardiologyFemaleFranceElderly individualbusinessCardiology and Cardiovascular MedicineSujet âgéFollow-Up StudiesCohort studyArchives of Cardiovascular Diseases
researchProduct